VivoSim Labs Share Price Today

VivoSim Labs to present 3D tissue safety data at ACT annual meeting

VivoSim Labs presents translational safety data at ACT 47th Annual Meeting. Event scheduled for November 15-18, 2026, in San Antonio, Texas. Data covers small molecules and antibody-drug conjugates (ADCs). Multiparametric approach offers superior predictive power over cell death alone.

VivoSim Labs and Chemveda partner to test AI drug candidates in human tissue

VivoSim Labs and Chemveda Life Sciences announced a strategic collaboration on November 3, 2026. The partnership integrates Chemveda's synthesis with VivoSim's human-relevant tissue models. VivoSim's NAMkind™ Liver model demonstrated 91% accuracy and 90% sensitivity in clinical datasets. First programs under the collaboration are expected to begin in Q4 2026.

VivoSim Labs shows NAMkind predicts liver, GI toxicity for ADCs at EUROTOX

VivoSim Labs presented data at EUROTOX 2026 showing its NAMkind platform predicts liver and GI toxicity for small molecules and ADCs. The NAMkind Liver platform supports up to 28-day viability, ranking trastuzumab deruxtecan as more hepatotoxic than trastuzumab emtansine. Intestinal models maintained barrier integrity for three weeks, with ileum tissue showing greater sensitivity to ADC toxicity than colon tissue. The FDA is advancing frameworks for New Approach Methodologies, creating a favorable industry backdrop for human-relevant alternatives to animal testing.

VivoSim Labs plans rat liver model to expand toxicology capabilities

VivoSim Labs plans to develop a rat liver model to complement its NAMkind human liver platform. The move aims to expand the company's liver toxicology capabilities. The model addresses the challenge that rat toxicity does not always translate to humans. It helps sponsors identify when adverse rat findings are species-specific.

VivoSim regains Nasdaq compliance with $10.1M cash after Eli Lilly payout

VivoSim Labs restored Nasdaq compliance with $10.1M cash, driven by a $5M Eli Lilly milestone, $1M escrow release, and $4M financing. The company issued nearly 10M new shares in July 2026 and forecasts over 500% revenue growth in FY27.

VivoSim enters China with NAMkind toxicology sales

VivoSim Labs, Inc. announced its first commercial sales in China for NAMkind toxicology and efficacy testing services through engagements with a Shanghai-based oncology biotech and a Chengdu-based pharmaceutical company. The NAMkind platform achieved 91% predictive accuracy in liver toxicology benchmarking, outperforming traditional animal models. The company targets a $2 billion addressable market in China, growing at 10% CAGR, supported by regulatory reforms and the FDA's move away from animal testing.